Uncategorized

Sanofi Keeps Immuno Deals Coming With Kali Bet Worth Potential $1B+

Published

2 weeks ago

on

Kali Therapeutics’ T cell engager, for which Sanofi is initially paying $180 million, could potentially be developed for a range of B cell–driven autoimmune disorders.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version